Aprea Therapeutics (APRE) Competitors

Aprea Therapeutics (NASDAQ:APRE) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

Which has stronger valuation & earnings, APRE or HOWL?

Aprea Therapeutics has higher earnings, but lower revenue than Werewolf Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aprea Therapeutics	$580K	17.24	-$14.29M	-$2.38	-0.76
Werewolf Therapeutics	$1.89M	20.71	-$37.37M	-$1.66	-0.52

Do institutionals & insiders have more ownership in APRE or HOWL?

34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are held by institutional investors. 12.8% of Aprea Therapeutics shares are held by company insiders. Comparatively, 21.1% of Werewolf Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Do analysts recommend APRE or HOWL?

Aprea Therapeutics currently has a consensus target price of $15.50, indicating a potential upside of 756.35%. Werewolf Therapeutics has a consensus target price of $9.00, indicating a potential upside of 933.41%. Given Werewolf Therapeutics' higher probable upside, analysts plainly believe Werewolf Therapeutics is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aprea Therapeutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Werewolf Therapeutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility and risk, APRE or HOWL?

Aprea Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Werewolf Therapeutics has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500.

Does the media favor APRE or HOWL?

In the previous week, Werewolf Therapeutics had 3 more articles in the media than Aprea Therapeutics. MarketBeat recorded 4 mentions for Werewolf Therapeutics and 1 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 1.87 beat Werewolf Therapeutics' score of -0.22 indicating that Aprea Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aprea Therapeutics	Very Positive
Werewolf Therapeutics	Neutral

Does the MarketBeat Community believe in APRE or HOWL?

Aprea Therapeutics received 22 more outperform votes than Werewolf Therapeutics when rated by MarketBeat users. However, 70.83% of users gave Werewolf Therapeutics an outperform vote while only 57.14% of users gave Aprea Therapeutics an outperform vote.

Company	Underperform	Outperform
Aprea Therapeutics	Outperform Votes 56 57.14%	Underperform Votes 42 42.86%
Werewolf Therapeutics	Outperform Votes 34 70.83%	Underperform Votes 14 29.17%

Is APRE or HOWL more profitable?

Werewolf Therapeutics has a net margin of -578.80% compared to Aprea Therapeutics' net margin of -1,029.50%. Aprea Therapeutics' return on equity of -57.86% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aprea Therapeutics	-1,029.50%	-57.86%	-47.94%
Werewolf Therapeutics	-578.80%	-58.83%	-38.45%

Summary

Werewolf Therapeutics beats Aprea Therapeutics on 12 of the 17 factors compared between the two stocks.